At a recent national conference, findings from a review of head and neck cancer treatments were presented, shedding light on a technique called proton re-irradiation. This approach is used when surgery isn't an option for tumors in tricky locations or when patients have previously undergone treatments that preclude further surgery. Taylor MacDonald, DO, the chief resident in the Department of Radiation Oncology at UC's College of Medicine, shared insights gathered from 84 cases. According to a UC article, over 63% of patients experienced disease progression within four months after the treatment, and the one-year overall survival rate stood at 33%.
With the struggle to establish a standard of care for recurrent head and neck cancer patients, the presented data is a valuable resource. MacDonald, highlighting the necessity for options, told UC News, "With no true standard of care for these recurrent patients, it is helpful to have proton therapy to offer as an option for local control and therapy." Despite the promise of re-irradiation, MacDonald acknowledged the high rates of Grade 3 toxicities, yet characterized the severe side effects as overall manageable.
The research indicates a pivotal role proton re-irradiation might play in treating certain cancer recurrences, especially as there is scarce long-term data available for patients treated with traditional photon therapy in this context. MacDonald emphasized the ongoing work to refine patient selection to mitigate risks and improve treatment outcomes, stating through UC News, "This highlights the importance of patient selection for re-irradiation in these recurrent head and neck cases."
Future research goals include a focus on base-of-skull recurrences specifically. These cases are traditionally treated with protons, but lack long-term photon treatment data. "We are particularly interested in looking at base-of-skull recurrences, since these patients are very specifically treated with protons and do not have long-term data in the photon realm," MacDonald said in an explanation given to UC News. Proton therapy, though with its challenges, still represents a critical avenue for those with limited treatment options. MacDonald's findings were detailed in her presentation titled "Evaluation of Efficacy and Safety of Proton Reirradiation in Head and Neck Cancers: Institutional Outcomes and Toxicity Profile Analysis" on September 29 at 1:45 p.m. Eastern time.
